diagnosis
Latest
Using Fast Periodic Visual Stimulation to measure cognitive function in dementia
Fast periodic visual stimulation (FPVS) has emerged as a promising tool for assessing cognitive function in individuals with dementia. This technique leverages electroencephalography (EEG) to measure brain responses to rapidly presented visual stimuli, offering a non-invasive and objective method for evaluating a range of cognitive functions. Unlike traditional cognitive assessments, FPVS does not rely on behavioural responses, making it particularly suitable for individuals with cognitive impairment. In this talk I will highlight a series of studies that have demonstrated its ability to detect subtle deficits in recognition memory, visual processing and attention in dementia patients using EEG in the lab, at home and in clinic. The method is quick, cost-effective, and scalable, utilizing widely available EEG technology. FPVS holds significant potential as a functional biomarker for early diagnosis and monitoring of dementia, paving the way for timely interventions and improved patient outcomes.
How AI is advancing Clinical Neuropsychology and Cognitive Neuroscience
This talk aims to highlight the immense potential of Artificial Intelligence (AI) in advancing the field of psychology and cognitive neuroscience. Through the integration of machine learning algorithms, big data analytics, and neuroimaging techniques, AI has the potential to revolutionize the way we study human cognition and brain characteristics. In this talk, I will highlight our latest scientific advancements in utilizing AI to gain deeper insights into variations in cognitive performance across the lifespan and along the continuum from healthy to pathological functioning. The presentation will showcase cutting-edge examples of AI-driven applications, such as deep learning for automated scoring of neuropsychological tests, natural language processing to characeterize semantic coherence of patients with psychosis, and other application to diagnose and treat psychiatric and neurological disorders. Furthermore, the talk will address the challenges and ethical considerations associated with using AI in psychological research, such as data privacy, bias, and interpretability. Finally, the talk will discuss future directions and opportunities for further advancements in this dynamic field.
Diagnosing dementia using Fastball neurocognitive assessment
Fastball is a novel, fast, passive biomarker of cognitive function, that uses cheap, scalable electroencephalography (EEG) technology. It is sensitive to early dementia; language, education, effort and anxiety independent and can be used in any setting including patients’ homes. It can capture a range of cognitive functions including semantic memory, recognition memory, attention and visual function. We have shown that Fastball is sensitive to cognitive dysfunction in Alzheimer’s disease and Mild Cognitive Impairment, with data collected in patients’ homes using low-cost portable EEG. We are now preparing for significant scale-up and the validation of Fastball in primary and secondary care.
The problem of power in single-case neuropsychology
Case-control comparisons are a gold standard method for diagnosing and researching neuropsychological deficits and dissociations at the single-case level. These statistical tests, developed by John Crawford and collaborators, provide quantitative criteria for the classical concepts of deficit, dissociation and double-dissociation. Much attention has been given to the control of Type I (false positive) errors for these tests, but far less to the avoidance of Type II (false negative) errors; that is, to statistical power. I will describe the origins and limits of statistical power for case-control comparisons, showing that there are hard upper limits on power, which have important implications for the design and interpretation of single-case studies. My aim is to stimulate discussion of the inferential status of single-case neuropsychological evidence, particularly with respect to contemporary ideals of open science and study preregistration.
diagnosis coverage
4 items